Q-omics provides the consensus-scored RMND5A profile across patient tissues and cancer cell-line models. RMND5A expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RMND5A is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, RMND5A RNA expression shows 25,738 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, KICH, and LSCC as cancer lineages where RMND5A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RMND5A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RMND5A survival associations across molecular data types. RMND5A RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RMND5A RNA expression–survival associations across cancer types. High RMND5A expression shows unfavorable associations in KIRP and ACC, but favorable associations in KIRC, THYM, LUSC and GBM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RMND5A RNA expression.
This table summarizes RMND5A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 3. The strongest signals are observed in KICH for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for RMND5A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RMND5A shows lower tumor expression in KICH, KIRC, COAD and LUAD and higher tumor expression in LUSC and BLCA. The KICH box plot shows higher RMND5A RNA expression in normal versus tumor tissue (log2 FC = −1.217, t-test p < 0.001).
This table shows molecular features associated with RMND5A in patient tissues and cancer cell lines. In patient samples, RMND5A shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, RMND5A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
